http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2754856-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2017-06-19^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-08^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4854a83330f2f4d3e8c7fc8d9fc5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74c5a128496096d8470d13c8c6f46448 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1da9877a01befb9bb314b4509c7391d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbfb3faf94b17979b517f072a9accc67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65586b424972bd23c3429bc2ca6cad88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a497aed28593b42b22093543146ce593 |
| publicationDate | 2021-09-08^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2754856-C2 |
| titleOfInvention | Crystal forms of triazolopyrimidine compound |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to a crystal form ofN-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridine-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidine-5-amine hydrochloride characterized by a powder X-ray diffraction pattern containing peaks at following values 2θ (CuKα λ=1.5418 Å), equal to 12.5±0.1, 13.0±0.1, 14.2±0.1, 18.7±0.1, 25.2±0.1 and 30.8±0.1. The invention also relates to a method for obtaining the specified crystal form ofN-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridine-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidine-5-amine hydrochloride, which includes following stages: 1) slurrying ofN-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridine-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidine-5-amine (Compound A) in a mixture of water and an organic solvent mixed with water selected from a group consisting of ethanol and acetone; 2) heating the resulting suspension to a temperature of approximately 50°C to 75°C; 3) acidification of the resulting suspension with hydrochloric acid to form a transparent solution, while maintaining the temperature of about 50°C to 75°C; and 4) lowering the temperature of the resulting solution to obtain the crystal form ofN-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridine-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidine-5-amine, where the mass fraction of the residual organic solvent contained in the specified crystal form is less than 0.5%.EFFECT: crystal form ofN-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridine-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidine-5-amine hydrochloride is obtained, which can be used in medicine in the treatment of a disease or disorder mediated by PRC2.7 cl, 11 dwg, 3 tbl, 4 ex |
| priorityDate | 2016-06-20^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 285 of 285.